BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Suven Life Sciences readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Suven Life Sciences's drugs run\,
  from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05397639-701@assetmemo.bio
DTSTAMP:20261121T005419Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Masupirdine: Phase 3 readout est. (NCT05397639)
DESCRIPTION:Masupirdine\, phase 3\, Alzheimer's Disease.\nStudy: Masupirdin
 e for the Treatment of Agitation in Dementia of the Alzheimer's Type\nEsti
 mated primary completion: December 2026. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/masupirdine#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT05397639
URL:https://assetmemo.bio/drug/masupirdine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
